2024
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, Khanna D, Guyatt G, Mirza R, Aggarwal R, Allen A, Assassi S, Buckley L, Chami H, Corwin D, Dellaripa P, Domsic R, Doyle T, Falardeau C, Frech T, Gibbons F, Hinchcliff M, Johnson C, Kanne J, Kim J, Lim S, Matson S, McMahan Z, Merck S, Nesbitt K, Scholand M, Shapiro L, Sharkey C, Summer R, Varga J, Warrier A, Agarwal S, Antin‐Ozerkis D, Bemiss B, Chowdhary V, D'Amico J, Hallowell R, Hinze A, Injean P, Jiwrajka N, Joerns E, Lee J, Makol A, McDermott G, Natalini J, Oldham J, Saygin D, Lakin K, Singh N, Solomon J, Sparks J, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Care & Research 2024, 76: 1070-1082. PMID: 38973729, DOI: 10.1002/acr.25347.Peer-Reviewed Original ResearchSystemic autoimmune rheumatic diseasesInterstitial lung diseasePulmonary function testsAutoimmune rheumatic diseasesMonitoring of interstitial lung diseaseChest radiographyHigh-resolution computed tomography of the chestInterstitial lung disease risk factorsLung diseaseChest PhysiciansInterstitial lung disease progressionAmerican CollegeDevelopment of interstitial lung diseaseRheumatic diseasesAmerican College of Chest PhysiciansHigh-resolution computed tomographyMonitoring interstitial lung diseasesSurgical lung biopsyIdiopathic inflammatory myopathiesConnective tissue diseaseClinical practice guidelinesWalk test distanceGrading of RecommendationsEvidence-based recommendationsLung biopsy2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, Khanna D, Guyatt G, Mirza R, Aggarwal R, Allen A, Assassi S, Buckley L, Chami H, Corwin D, Dellaripa P, Domsic R, Doyle T, Falardeau C, Frech T, Gibbons F, Hinchcliff M, Johnson C, Kanne J, Kim J, Lim S, Matson S, McMahan Z, Merck S, Nesbitt K, Scholand M, Shapiro L, Sharkey C, Summer R, Varga J, Warrier A, Agarwal S, Antin‐Ozerkis D, Bemiss B, Chowdhary V, D'Amico J, Hallowell R, Hinze A, Injean P, Jiwrajka N, Joerns E, Lee J, Makol A, McDermott G, Natalini J, Oldham J, Saygin D, Lakin K, Singh N, Solomon J, Sparks J, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis & Rheumatology 2024, 76: 1201-1213. PMID: 38973714, DOI: 10.1002/art.42860.Peer-Reviewed Original ResearchSystemic autoimmune rheumatic diseasesInterstitial lung diseasePulmonary function testsAutoimmune rheumatic diseasesMonitoring of interstitial lung diseaseChest radiographyHigh-resolution computed tomography of the chestInterstitial lung disease risk factorsLung diseaseChest PhysiciansInterstitial lung disease progressionAmerican CollegeDevelopment of interstitial lung diseaseRheumatic diseasesAmerican College of Chest PhysiciansHigh-resolution computed tomographyMonitoring interstitial lung diseasesSurgical lung biopsyIdiopathic inflammatory myopathiesConnective tissue diseaseClinical practice guidelinesWalk test distanceGrading of RecommendationsEvidence-based recommendationsLung biopsy2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, Khanna D, Guyatt G, Mirza R, Aggarwal R, Allen A, Assassi S, Buckley L, Chami H, Corwin D, Dellaripa P, Domsic R, Doyle T, Falardeau C, Frech T, Gibbons F, Hinchcliff M, Johnson C, Kanne J, Kim J, Lim S, Matson S, McMahan Z, Merck S, Nesbitt K, Scholand M, Shapiro L, Sharkey C, Summer R, Varga J, Warrier A, Agarwal S, Antin‐Ozerkis D, Bemiss B, Chowdhary V, D'Amico J, Hallowell R, Hinze A, Injean P, Jiwrajka N, Joerns E, Lee J, Makol A, McDermott G, Natalini J, Oldham J, Saygin D, Lakin K, Singh N, Solomon J, Sparks J, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis & Rheumatology 2024, 76: 1182-1200. PMID: 38978310, DOI: 10.1002/art.42861.Peer-Reviewed Original ResearchTreatment of interstitial lung diseaseSystemic autoimmune rheumatic diseasesInterstitial lung diseaseAutoimmune rheumatic diseasesLung diseaseChest PhysiciansInterstitial lung disease progressionAmerican CollegeProgressive interstitial lung diseaseRheumatic diseasesAmerican College of Chest PhysiciansClinical practice guidelinesGrading of RecommendationsEvidence-based recommendationsClinically relevant populationOutcome questionsPractice guidelinesSystematic literature reviewDiseasePhysiciansTreatmentGlucocorticoidTherapyRelevant populationRecommendations2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, Khanna D, Guyatt G, Mirza R, Aggarwal R, Allen A, Assassi S, Buckley L, Chami H, Corwin D, Dellaripa P, Domsic R, Doyle T, Falardeau C, Frech T, Gibbons F, Hinchcliff M, Johnson C, Kanne J, Kim J, Lim S, Matson S, McMahan Z, Merck S, Nesbitt K, Scholand M, Shapiro L, Sharkey C, Summer R, Varga J, Warrier A, Agarwal S, Antin‐Ozerkis D, Bemiss B, Chowdhary V, D'Amico J, Hallowell R, Hinze A, Injean P, Jiwrajka N, Joerns E, Lee J, Makol A, McDermott G, Natalini J, Oldham J, Saygin D, Lakin K, Singh N, Solomon J, Sparks J, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Care & Research 2024, 76: 1051-1069. PMID: 38973731, DOI: 10.1002/acr.25348.Peer-Reviewed Original ResearchTreatment of interstitial lung diseaseSystemic autoimmune rheumatic diseasesInterstitial lung diseaseAutoimmune rheumatic diseasesLung diseaseChest PhysiciansInterstitial lung disease progressionAmerican CollegeProgressive interstitial lung diseaseRheumatic diseasesAmerican College of Chest PhysiciansClinical practice guidelinesGrading of RecommendationsEvidence-based recommendationsClinically relevant populationOutcome questionsPractice guidelinesSystematic literature reviewDiseasePhysiciansTreatmentGlucocorticoidTherapyRelevant populationRecommendations
2019
Is Immune Checkpoint Inhibitor Treatment an Option for Patients With Rheumatic Diseases and Cancer?
Buckley L, Suarez‐Almazor M. Is Immune Checkpoint Inhibitor Treatment an Option for Patients With Rheumatic Diseases and Cancer? Arthritis & Rheumatology 2019, 71: 1971-1973. PMID: 31379056, DOI: 10.1002/art.41064.Peer-Reviewed Original Research
2018
Talking with Patients about the Personal Impact of Illness, The Doctor’s Role
Buckley L, Frank A. Talking with Patients about the Personal Impact of Illness, The Doctor’s Role. 2018 DOI: 10.1201/9781315384108.Peer-Reviewed Original Research
2017
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis
Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Robinson AB, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis. Arthritis & Rheumatology 2017, 69: 1521-1537. PMID: 28585373, DOI: 10.1002/art.40137.Peer-Reviewed Original ResearchConceptsOral bisphosphonate treatmentGlucocorticoid-induced osteoporosisVitamin DGC treatmentAntifracture medicationsBisphosphonate treatmentFracture riskGC usersHigh-dose GC treatmentLong-term glucocorticoid treatmentLong-term GC treatmentSpecial populationsHarms of interventionsHigh fracture riskLower fracture riskQuality of evidenceGeneral adult populationBisphosphonate regimenGIOP preventionOral bisphosphonatesOsteoporosis medicationsRheumatology guidelinesDenosumab treatmentLifestyle modificationRecommendations Assessment
2016
Thromboelastography in the Characterization of Coagulation Status in Antiphospholipid Syndrome
Wallace N, Dumont A, Burns A, Christopher T, Rinder H, Kriegel M, Buckley L, Erkan D, Lee A. Thromboelastography in the Characterization of Coagulation Status in Antiphospholipid Syndrome. Blood 2016, 128: 4983. DOI: 10.1182/blood.v128.22.4983.4983.Peer-Reviewed Original ResearchLupus anticoagulant-hypoprothrombinemia syndromePartial thromboplastin timeAntiphospholipid syndromeImmune thrombocytopeniaAntiphospholipid antibodiesAPS patientsProthrombin timeCessation of anticoagulationGlycoprotein 1 antibodiesObstetrical antiphospholipid syndromeRole of thromboelastographySevere hemorrhagic complicationsSpecific coagulation defectsCatastrophic antiphospholipid syndromeChronic liver diseaseGlobal hemostasis assaysTraditional laboratory markersBaseline prolongationChronic aspirinPersistent positivityAdrenal hemorrhageAnticardiolipin antibodiesHemorrhagic complicationsImmunomodulatory treatmentAnticardiolipin IgG
2009
Reply
Desai S, Solomon D, Abramson S, Buckley L, Crofford L, Cush J, Lovell D, Saag K, Drugs A. Reply. Arthritis & Rheumatism 2009, 61: 285-286. DOI: 10.1002/art.24171.Peer-Reviewed Original Research
2002
Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial
Cushman M, Costantino J, Bovill E, Wickerham D, Buckley L, Roberts J, Krag D. Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial. British Journal Of Haematology 2002, 120: 109-116. PMID: 12492585, DOI: 10.1046/j.1365-2141.2003.03976.x.Peer-Reviewed Original ResearchConceptsBreast Cancer Prevention TrialVenous thrombosis risk factorsActivated protein CEffects of tamoxifenCancer Prevention TrialThrombosis risk factorsRisk factorsProtein CProtein SVenous thrombosisTamoxifen reduces breast cancer incidenceIncreased riskIncreased risk of venous thrombosisPrevention trialsActivated protein C resistanceRisk of venous thrombosisPlacebo-treated womenReduction of antithrombinTamoxifen-treated womenDouble-blind fashionMonths of treatmentActivated protein C ratioBreast cancer incidenceProtein C antigenBody mass index
2001
Tamoxifen and Cardiac Risk Factors in Healthy Women: Suggestion of an Anti-Inflammatory Effect
Cushman M, Costantino J, Tracy R, Song K, Buckley L, Roberts J, Krag D. Tamoxifen and Cardiac Risk Factors in Healthy Women: Suggestion of an Anti-Inflammatory Effect. Obstetrical & Gynecological Survey 2001, 56: 556-557. DOI: 10.1097/00006254-200109000-00019.Peer-Reviewed Original ResearchWorsening of Macrophage Activation Syndrome in a Patient with Adult Onset Still’s Disease after Initiation of Etanercept Therapy
Stern A, Riley R, Buckley L. Worsening of Macrophage Activation Syndrome in a Patient with Adult Onset Still’s Disease after Initiation of Etanercept Therapy. JCR Journal Of Clinical Rheumatology 2001, 7: 252-256. PMID: 17039144, DOI: 10.1097/00124743-200108000-00013.Peer-Reviewed Original ResearchMacrophage activation syndromeActivation syndromeSoluble tumor necrosis factor-alpha receptorEpstein-Barr virus infectionNonsteroidal anti-inflammatory drugsChildhood rheumatic disordersDramatic clinical improvementUse of etanerceptTumor necrosis factor-alpha receptorPeriod of feverAnti-inflammatory drugsEtanercept therapyClinical improvementPulse corticosteroidsLymph nodesParenteral goldRheumatic disordersClinical syndromeHistopathological examinationAdult onsetVirus infectionInfectious processPharmacological agentsBone marrowMononuclear phagocytesTamoxifen and Cardiac Risk Factors in Healthy Women
Cushman M, Costantino J, Tracy R, Song K, Buckley L, Roberts J, Krag D. Tamoxifen and Cardiac Risk Factors in Healthy Women. Arteriosclerosis Thrombosis And Vascular Biology 2001, 21: 255-261. PMID: 11156862, DOI: 10.1161/01.atv.21.2.255.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAnti-Inflammatory AgentsAntineoplastic Agents, HormonalBlood CoagulationBreast NeoplasmsC-Reactive ProteinCardiovascular DiseasesCardiovascular SystemCholesterolDouble-Blind MethodFemaleFibrinogenHumansPlacebosPostmenopauseRisk FactorsSelective Estrogen Receptor ModulatorsTamoxifenConceptsEffects of tamoxifenBreast Cancer Prevention TrialIncidence of breast cancerCardiovascular disease risk factorsHigh waist-to-hip ratioWaist-to-hip ratioHealthy womenDisease risk factorsRisk factorsCancer Prevention TrialAssociated with venous thrombosisFactor VII coagulant activityAssociation of tamoxifenFactors related to inflammationEffects of oral tamoxifenCardiac risk factorsC-reactive proteinVII coagulant activitySecondary analysisPrevention trialsMedian fibrinogenOral tamoxifenPostmenopausal womenPostmenopausal estrogenVenous thrombosis
2000
Obstacles to Promotion? Values of Women Faculty about Career Success and Recognition
Buckley L, Sanders K, Shih M, Kallar S, Hampton C. Obstacles to Promotion? Values of Women Faculty about Career Success and Recognition. Academic Medicine 2000, 75: 283-288. PMID: 10724319, DOI: 10.1097/00001888-200003000-00021.Peer-Reviewed Original Research
1999
Prevention of corticosteroid‐induced osteoporosis: Results of a patient survey
Buckley L, Marquez M, Feezor R, Ruffin D, Benson L. Prevention of corticosteroid‐induced osteoporosis: Results of a patient survey. Arthritis & Rheumatism 1999, 42: 1736-1739. PMID: 10446875, DOI: 10.1002/1529-0131(199908)42:8<1736::aid-anr24>3.0.co;2-e.Peer-Reviewed Original ResearchConceptsBone density testingCorticosteroid-induced osteoporosisCorticosteroid treatmentPreventive treatmentLong-term oral corticosteroid treatmentLong-term corticosteroid usersLong-term corticosteroid treatmentDensity testingMean prednisone doseOral corticosteroid treatmentBone density testHormone replacement therapyPrimary care physiciansStandard of careCorticosteroid usersPMP womenPrednisone dosePostmenopausal womenBisphosphonate treatmentCare physiciansOsteoporosis preventionBone lossReplacement therapyCalcium supplementsPatient survey
1998
Perceptions of Pharmacists about Adverse Effects of Corticosteroid Therapy: Focus on Osteoporosis
Hudson J, Small R, Buckley L. Perceptions of Pharmacists about Adverse Effects of Corticosteroid Therapy: Focus on Osteoporosis. Journal Of The American Pharmacists Association 1998, 38: 710-716. PMID: 9861789, DOI: 10.1016/s1086-5802(16)30392-8.Peer-Reviewed Original ResearchConceptsCorticosteroid therapyPerceptions of pharmacistsCorticosteroid usePostmenopausal womenPremenopausal womenAdverse effectsPatient counselingHigh-dose corticosteroid useWeight gainCorticosteroid-induced osteoporosisHigh-dose corticosteroidsHigh-dose therapyDrug-induced complicationsPrevention of osteoporosisPrednisone useBone densityOsteoporosisHospital pharmacistsMailed surveyTherapyMood changesPharmacistsWomenRespondents' knowledgeCorticosteroidsVariations in physicians' judgments about corticosteroid induced osteoporosis by physician specialty.
Buckley L, Marquez M, Hudson J, Downs R, Vacek P, Small R, Poses R. Variations in physicians' judgments about corticosteroid induced osteoporosis by physician specialty. The Journal Of Rheumatology 1998, 25: 2195-202. PMID: 9818664.Peer-Reviewed Original ResearchConceptsEstrogen replacement therapyCorticosteroid treatmentPhysician judgmentCorticosteroid usePhysician specialtySide effectsPostmenopausal patientsVitamin DBone lossReplacement therapyCorticosteroid-induced osteoporosisImportance of osteoporosisVitamin D supplementationMajority of patientsRisk of osteoporosisPrimary care physiciansSignificant side effectsHypothetical clinical scenariosImportance of corticosteroidsEfficacy of treatmentD supplementationPostmenopausal womenPremenopausal womenPhysician assessmentCare physicians
1997
A cross sectional assessment of health status instruments in patients with rheumatoid arthritis participating in a clinical trial. Minocycline in Rheumatoid Arthritis Trial Group.
Tuttleman M, Pillemer S, Tilley B, Fowler S, Buckley L, Alarcón G, Trentham D, Neuner R, Clegg D, Leisen J, Heyse S. A cross sectional assessment of health status instruments in patients with rheumatoid arthritis participating in a clinical trial. Minocycline in Rheumatoid Arthritis Trial Group. The Journal Of Rheumatology 1997, 24: 1910-5. PMID: 9330931.Peer-Reviewed Original ResearchConceptsPatient global assessmentSF-36Rheumatoid arthritisM-HAQOutcome measuresClinical trialsGlobal assessmentShort Form Health SurveyFunctional health status measuresJoint swelling scoreRA clinical trialsRA outcome measuresHealth Assessment QuestionnaireHealth status instrumentsSF-36 scalesRheumatoid arthritis trialsHealth status measuresMultitrait scaling analysisCross-sectional assessmentCross-sectional analysisMIRA trialStudy patientsRA populationScore correlationsPain itemsImportance of guidelines on glucocorticoid‐induced osteoporosis: Comment on the American college of rheumatology recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis
Buckley L. Importance of guidelines on glucocorticoid‐induced osteoporosis: Comment on the American college of rheumatology recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis. Arthritis & Rheumatism 1997, 40: 1547-1547. PMID: 9259442, DOI: 10.1002/art.1780400829.Peer-Reviewed Original ResearchEffects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis.
Buckley L, Leib E, Cartularo K, Vacek P, Cooper S. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. The Journal Of Rheumatology 1997, 24: 1489-94. PMID: 9263140.Peer-Reviewed Original ResearchConceptsBone mineral densityLow-dose methotrexateRheumatoid arthritisLumbar spineFemoral neckDose methotrexateMineral densityBMD of patientsFemoral neck bone mineral densityNeck bone mineral densitySpine bone mineral densityMeasurement of BMDAntirheumatic drug useVitamin D3 supplementationYears of followupGreater bone lossDMARD useD3 supplementationFollowup visitMTX useBone lossPrednisoneSimilar dosePatientsMethotrexate
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply